The company said net sales for the three and six months ended June 30, 2024 decreased 5% from the same periods a year earlier, and organic net sales decreased 4% and 5%, respectively. The company cited lower volumes tied to market conditions in the Health & Science Technologies business as the main factor.

1. 01

   The company said net sales for the three and six months ended June 30, 2024 decreased 5% from the same periods a year earlier, and organic net sales decreased 4% and 5%, respectively. The company cited lower volumes tied to market conditions in the Health & Science Technologies business as the main factor.

2. 02

   The company said it sold Alfa Valvole, Srl in 2024 for net cash proceeds of $45.5 million, and recognized a gain of $4.6 million on the sale, which reflected a release of cumulative foreign currency translation losses of $5.5 million. Its effective tax rate was 21.2% for the 3 months and 21.4% for the 6 months, compared with 22.4% and 22.3% in the same periods of the prior year.

3. 03

   The company said operating cash flow for the first 6 months of 2024 increased $1.1 million to $290.2 million. Capital expenditures were $35.9 million and dividend payments were $100.7 million over the same period, and it repaid $25.0 million of the $50.0 million previously outstanding under the Term Facility.

4. 04

   IDEX said on July 23, 2024 that it entered into a definitive agreement to acquire Mott Corporation and its subsidiaries for cash consideration of $1.0 billion, subject to customary adjustments. The company said it expects to fund the acquisition with cash on hand, borrowings under the Revolving Credit Facility and potential debt issuance.

Key figures

Quarter ended June 30, 2024

Revenue

$807M

Operating income

$183M

Net income

$141M

EPS

$1.86

Gross profit

$367M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.